This is the authors' abstract. We don't add key points for this paper.
The paper by Metrebian et al. 1 offers an excellent opportunity to discuss some major issues of addiction treatment research. First, the traditional hierarchy of treatment goals in the addiction field neglects the causal and modifying role of health and social factors on addictive behaviour, suggesting replacing the reduction of substance use by an individualized quality of life as the ultimate goal. Secondly, comparing the outcomes of randomized controlled trials (RCTs) on heroin-assisted treatment (HAT) is problematic; more to the point is an added benefit for HAT over controls in all trials. Implications for treatment research concern the interactions of risk factors for developing and sustaining addictive behaviour, the need for prospective cohort studies and extended follow-up periods to complement the RCTs as evidence for treatment effectiveness under real-world conditions. Finally, treatment policy might profit from control groups in HAT trials learning about deficits in conventional opiate substitution treatment, and from the economic benefits of HAT over optimized substitution treatments. In general, treatment policy will have to define national priorities for outcomes in terms of public versus researcher preferences. The Randomized Injectable Opioid Treatment Trial (RIOTT) paper 1 presents detailed findings on health and social change under the heading of secondary outcomes. The reduction of substance use is considered the primary goal of interventions. A high-level expert group mandated by the National Institute on Drug Abuse NIDA concluded in 2012 that: ‘Drug-taking behavior is seen as the most appropriate proximal primary outcome in drug dependence treatment clinical trials’ 2. This was justified as long as the use of addictive substances was considered the main or only causing factor of health and social problems linked to the dependence syndrome. However, things have moved, and addiction is recognized as a complex interaction of multiple factors: substance, personality characteristics, environmental stress and deficient alternative options for pleasurable experiences. Addictive behaviour may be equally fostered by health and/or social problems, and environmental determinants have a major role in shaping health and social consequences of use 3. Poverty, educational deficits and migration with disruption of social networks and support are all factors correlated with substance use and dependence, while a range of mental health problems leads to substance use as a kind of self-medication 4. According to brain research, environmental stress facilitates the passage from frequent use to dependence 5. All this has consequences for treatment goals. A seminal paper made it clear: ‘The cessation or reduction of addictive behavior is often a good starting-point, but if that is where treatment ends, it may be finishing just when a person needs help the most’ 6. Also, the order is reversed in all replacement therapies aiming at social and health stabilization before eventually withdrawing the addictive substance. For the recovery movement, abstinence is not enough and must be complemented by good social functioning 7. The pyramid of treatment goals is no longer topped by abstinence or reduction of use. A subjectively defined quality of life, instead of being a ‘secondary outcome’ 8, makes a good replacement at the top: ‘One area of study that holds worthwhile insights for addressing addiction is research on quality of life and more specifically, subjective wellbeing’ 6. Different findings in health and social outcomes from other RCTs on HAT are linked to differences in evaluation profile and methodologies. The German trial had an entry criterion of ‘poor physical and/or mental health with at least 13 symptoms on the Opiate Treatment Index OTI’ 9, and the Dutch trials had an entry criterion of ‘poor physical or mental health’, including those not stabilized on psychiatric medication [10], while in RIOTT any ‘active significant medical or psychiatric condition’ was excluded [11]. Participants were recruited from methadone programmes [1, 10], but also from the street being out of treatment [9, 12, 13]. The following instruments for initial assessments were used: DSM-IV [10], Symptom Checklist Index-90 (SCL-90) [10], SCL-90-R [9], Opiate Treatment Index (OTI) [9,12], Short Form (SF)-12 [12], Addiction Severity Index (ASI) [12], Europ-ASI [13] and the SF Health Survey [14], plus diverse laboratory data. Outcome measurements and responder definition varied across trials ([15], p. 38), and differences in treatment regimens were substantial with regard to dosages ([15], p. 39). Follow-up periods range from 6 (1) to 9 (12) to 12 (9, 10) months. These differences may contribute to differences in outcome. More important seems the consistent finding that some added value of HAT over control groups is in evidence across all trials. Given the interaction of the diverse risk factors for developing addictive behaviour, it is useful to collect data on risk indicators. Comparing outcomes from different trials would be limited to interventions in comparable risk constellations, e.g. in specific target groups. Furthermore, effectiveness of treatment under real-world conditions differs from efficacy under experimental conditions. Prospective cohort studies with patients receiving treatment according to their needs and not to randomization must complement the findings from RCTs, and longer follow-up periods are relevant for knowing stable outcomes. Examples include the National Treatment Outcome Research Study (NTOR), which showed stability of outcomes over 5 years 16 and the Drug Treatment Outcome Research Study (DTOR), which showed interactions of social factors and drug-using behaviour 17. A remarkable finding from the RIOTT study is the poor outcome of conventional methadone maintenance (CMM) as experienced prior to the trial, in comparison to optimized oral methadone (OOM) in the trial. This is an invitation to improve concept and practice of clinics and other providers. Upscaling HAT for patients failing in OMM is suggested by a better reduction in crime 1, accounting for lower costs when compared to OOM 18. Policy should also include decisions about where the priorities for treatment goals and evaluation of outcomes are, in response to the main problems in a given country 19. Evidence from treatment evaluation invites a revision of treatment objectives and of treatment research and policy orientation. None.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ambros Uchtenhagen (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: